Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel

Cancer Science

Volumn 99, Issue 3, 2008, Pages 601-607

  Kageyama, Shinichi ^a   Kitano, Shigehisa ^a   Hirayama, Michiko ^a   Nagata, Yasuhiro ^b   Imai, Hiroshi ^a   Shiraishi, Taizo ^a   Akiyoshi, Kazunari ^c   Scott, Andrew M ^d   Murphy, Roger ^d   Hoffman, Eric W ^d   Old, Lloyd J ^d   Katayama, Naoyuki ^a   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID DERIVATIVE; CANCER VACCINE; CHOLESTERYL PULLULAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; IMMUNOGLOBULIN G ANTIBODY; PEPTIDE DERIVATIVE; PICIBANIL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; AGED; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTICLE; BREAST CANCER; CANCER CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEOPLASM; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION;

EID: 38949116978     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00705.x     Document Type: Article

References (25)

1. Gu XG, Schmitt M, Hiasa A et al. A novel hydrophobized polysaccharide/ oncoprotein complex vaccine induces in.vitro and in.vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res 1998; 58: 3385-90.
2. Kitano S, Kageyama S, Nagata Y et al. HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 2006; 12: 7397-405.
3. Kawabata R, Wada H, Isobe M et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 2007; 120: 2178-84.
4. Uenaka A, Wada H, Isobe M et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immunity 2007; 7: 9-20.
5. Okamoto M, Furuichi S, Nishioka Y et al. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res 2004; 64: 5461-70.
6. Stockert E, Jäger E, Chen Y et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187: 1349-54.
7. Valerius T, Repp R, de Wit TP et al. Involvement of the high-affinity receptor for IgG (FcRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy. Blood 1993; 82: 931-9.
8. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997; 15: 3363-7.
9. Bei R, Masuelli L, Moriconi E et al. Immune responses to all ErbB family receptors detectable in serum of cancer patients. Oncogene 1999; 18: 1267-75.
10. Disis ML, Knutson KL, Schiffman K et al. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 2000; 62: 245-52.
11. Montgomery RB, Makary E, Schiffman K, Goodell V, Disis ML. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 2005; 65: 650-6.
12. + Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas. J Immunol 2005; 174: 4228-36.
13. Reilly RT, Machiels JPH, Emens LA et al. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res 2001; 61: 880-3.
14. Renard V, Sonderbye L, Ebbehøj K et al. HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 2003; 171: 1588-95.
15. Nagata Y, Ono S, Matsuo M et al. Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci USA 2002; 99: 10.629-34.
16. Matsuo M, Nagata Y, Sato E et al. IFN-γ enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc Natl Acad Sci USA 2004; 101: 14.467-72.
17. Valmori D, Souleimanian NE, Tosello V et al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007; 104: 8947-52.
18. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Nat Acad Sci USA 1993; 90: 3539-43.
19. Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex.vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-46.
20. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22: 3188-92.
21. Disis ML, Bernhard H, Shiota FM et al. Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines. Blood 1996; 88: 202-10.
22. Jäger E, Ringhoffer M, Dienes HP et al. Granulocyte-macrophage colony stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer 1996; 67: 54-62.
23. Slingluff CL, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003; 21: 4016-26.
24. Cruciani M, Mengoli C, Serpelloni G, Mazzi R, Bosco O, Malena M. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: A meta-analysis. Vaccine 2007; 25: 709-18.
25. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 2004; 10: 3273-81.